Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Change in the clinical development program for laquinimod
Glatiramer acetate in the treatment of multiple sclerosis
4th Biannual NeuroUnit Biomarkers for Inflammation and Neurodegeneration Symposium on Biomarkers in Neurodegenerative Disease
Gender identity disorders and multiple sclerosis risk: A national record-linkage study.
Dimethyl fumarate modulates antioxidant and lipid metabolism in oligodendrocytes.
Oral ponesimod in relapsing-remitting multiple sclerosis: a randomised phase II trial.
Gordon Research Conference on Immunochemistry & Immunobiology
Effect of the Kv7-channel Opener Flupirtine on the Excitability of Human Peripheral Myelinated Axons in Vivo
Synthetic Biologics Announces Issuance of U.S. Patent Adding Another Layer of Protection for the Use of Oral Estriol Candidate, Trimesta™, for Multiple Sclerosis
Efficacy of remission-induction regimens for ANCA-associated vasculitis.
Siponimod for patients with relapsing-remitting multiple sclerosis (BOLD): an adaptive, dose-ranging, randomised, phase 2 study.
Oxidative modification of serum proteins in multiple sclerosis.
Glatiramer acetate ameliorates experimental autoimmune neuritis.
Emotional Change-Associated T Cell Mobilization at the Early Stage of a Mouse Model of Multiple Sclerosis.
Acid-sensing ion channel-1 contributes to axonal degeneration in autoimmune inflammation of the central nervous system.
Uhthoff's phenomena in MS-clinical features and pathophysiology.
Gait Mechanics are Different between Healthy Controls and Patients with Multiple Sclerosis.
The effect of daclizumab on brain atrophy in relapsing-remitting multiple sclerosis.
Mechanical environment modulates biological properties of oligodendrocyte progenitor cells.
The INCAT disability score: A critical analysis of its measurement properties.
New York Academy of Sciences: T Cells at the Interface of Immune-CNS Cross-Talk
Rituximab in relapsing and progressive forms of multiple sclerosis: a systematic review.
Dose titration of BAF312 attenuates the initial heart rate reducing effect in healthy subjects.
Risks vs benefits of glatiramer acetate: a changing perspective as new therapies emerge for multiple sclerosis.
Temporal relationship between elevation of epstein-barr virus antibody titers and initial onset of neurological symptoms in multiple sclerosis.

Pages